Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents

Bibliography

• Bays H, Stein EA. Pharmacotheraphy for dyslipidemia-current therapies and future agents. Expert Opin Pharmacother 2003;4:1901-38
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977;62:707-14
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Rifkind BM. High-density lipoprotein – the clinical implications of recent studies. N Engl J Med 1989;321:1311-16
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RL, et al. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
   PubMed Web of Science ®Google Scholar
• Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs high-density lipoprotein intervention trial. Am J Cardiol 2000;86:19L-22L
   PubMed Web of Science ®Google Scholar
• Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-74
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brewer HBJ, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Thromb Vasc Biol 2003;23:160-7
   PubMed Web of Science ®Google Scholar
• De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, De Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8
   PubMed Web of Science ®Google Scholar
• Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15
   PubMed Web of Science ®Google Scholar
• Sikorski JA. Cholesteryl ester transfer protein inhibitors as potential new therapies for coronary artery disease. Expert Opin Ther Patents 2006;16:753-72
   Web of Science ®Google Scholar
• Sikorski JA. Oral cholesteryl ester transfer inhibitors: a potential new approach for treating coronary artery disease. J Med Chem 2006;49:1-22
   PubMed Web of Science ®Google Scholar
• Shinkai H, Maeda K, Yamasaki T, et al. Bis(2-(acylamino)phenyl) disufides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J Med Chem 2000;43:3566-72
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7
   PubMed Web of Science ®Google Scholar
• Japan Tobacco, Inc. CETP activity inhibitors for use in the treatment of hyperlipidemia and atherosclerosis. WO09835937; 1998
   Google Scholar
• Qiu X, Mistry A, Ammirati MJ, et al. Crystal structure of cholestery ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol 2007;14:106-13
   PubMed Web of Science ®Google Scholar
• Pfizer Products, Inc. Novel 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors. EP00987251; 2000
   Google Scholar
• Pfizer Products, Inc. Novel 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as CETP inhibitors. WO00017164; 2000
   Google Scholar
• Pfizer Products, Inc. Novel 4-amino-substituted-2-substituted-1,2,3,4-tetrahydroquinolines as CETP inhibitors. WO00017165; 2000
   Google Scholar
• Pfizer Products, Inc. Novel 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors. WO00017166; 2000
   Google Scholar
• Pfizer Products, Inc. Novel annulated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines useful as CETP inhibitors. EP00992496; 2000
   Google Scholar
• Pfizer Products, Inc. New N-(3,5-bis-trifluoromethyl-benzyl)-N-(6-trifluoromethyl-1,2,3,4-tetrahydro-quinolin-4-yl)-amine derivatives are CETP inhibitors - useful for the treatment of atherosclerosis. WO2005033082; 2005
   Google Scholar
• Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand Whikte rabbits. J Lipd Res 2007;48:1267-72
   Google Scholar
• Japan Tobacco, Inc. CETP inhibitors useful in the treatment of arteriosclerosis and hyperlipidemia. JP2003221376; 2003
   Google Scholar
• Japan Tobacco, Inc. Dibenzylamine compound and medicinal use thereof. WO2004020393; 2004
   Google Scholar
• Eli Lilly & Co. New fused hexahydro-1H-azepine and octahydroazocine derivatives are CETP modulators – useful for the treatment of lipid metabolism disorders. WO2005097805; 2005
   Google Scholar
• Merck & Co, Inc. New N,N-dibenzylamine derivatives are inhibitors of cholesterol ester transfer protein – useful for the treatment of atherosclerosis. WO2005100298; 2005
   Google Scholar
• Merck & Co, Inc. New substituted phenyl derivatives are CETP inhibitors – useful for the prevention and treatment of atherosclerosis. WO2007041494; 2007
   Google Scholar
• Merck & Co, Inc. New substituted biphenyl compounds are CETP inhibitors - useful for the prevention and treatment of atherosclerosis. WO2007047591; 2007
   Google Scholar
• Merck & Co, Inc. New azole derivatives are CETP inhibitors – useful for the treatment of atherosclerosis. WO2006014357; 2006
   Google Scholar
• Merck & Co, Inc. New oxazolidinone and related heterocyclic derivatives are CETP inhibitors – useful for the treatment of atherosclerosis. WO2007079186; 2007
   Google Scholar
• Merck & Co, Inc. New substituted heterocyclic compounds are CETP inhibitors – useful for raising HDL-C, lowering LDL-C and for the treatment of atherosclerosis. WO2007081570; 2007
   Google Scholar
• Merck & Co, Inc. New substituted cyclic compounds are CETP inhibitors – useful for raising HDL-C, lowering LDL-C and the treatment of atherosclerosis. WO2007081571; 2007
   Google Scholar
• Vergeer M, Kastelein JJP. Anacetrapib: new hope for cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia. Nat Clin Pract Cardiovasc Med 2008;5:302-3
   Google Scholar
• Tanabe Seiyaku Co. Ltd. New tetrahydroquinoline derivatives are CETP inhibitors – useful for treating e.g. cardiovascular diseases, diabetes and obesity. WO2005095409; 2005
   Google Scholar
• Tanabe Seiyaku Co. Ltd. New tetrahydronaphthyridine derivatives are CETP inhibitors – useful for treating e.g. cardiovascular diseases, diabetes and obesity. WO2005095395; 2005
   Google Scholar
• Tanabe Seiyaku Co. Ltd. New trisubstituted amine derivatives are CETP inhibitors – useful for the treatment of arteriosclerotic diseases, hyperlipidemia or dyslipidemia. WO2007088996; 2007
   Google Scholar
• Tanabe Seiyaku Co. Ltd. New trisubstituted amine derivatives are CETP inhibitors – useful for the treatment of arteriosclerotic diseases, hyperlipidemia or dyslipidemia. WO2007088999; 2007
   Google Scholar
• Array BioPharma, Inc. New substituted dihydroquinoline compounds are cholesterol ester transfer protein inhibitors – useful for the treatment of e.g. atherosclerosis, coronary artery disease, hypertension, diabetes mellitus and inflammation. US20060270675; 2006
   Google Scholar
• Reddy US Therapeutics, Inc. New benzylamine derivatives are CETP inhibitors – useful for the treatment of lipoprotein metabolism disorders. WO2006073973; 2006
   Google Scholar
• Novartis AG. New pyridinyl amine derivatives are CETP inhibitors – useful for the treatment of eg hyperlipidemia, atherosclerosis, coronary heart disease, stroke and diabetes type II. WO2007073934; 2007
   Google Scholar
• Novartis AG. New bicyclic derivatives are CETP inhibitors – useful for the treatment of eg hyperlipidemia and atherosclerosis. WO2007128568; 2007
   Google Scholar
• Novartis AG. New benzylamine derivatives are CETP inhibitors – useful for the treatment of eg dyslipidemia, cardiovascular disease, stroke, diabetes and obesity. WO2007132906; 2007
   Google Scholar
• Novartis AG. New amino-piperidine derivatives are CETP inhibitors – useful for the treatment of eg atherosclerosis, dyslipidemia, stroke, reperfusion injury, hypertension, diabetes type II and obesity. WO2008009435; 2008
   Google Scholar
• Novartis AG. New pyridine and pyrazine derivatives are CETP inhibitors – useful for the treatment of eg lipid metabolism disorders, cardiovascular disease, stroke, diabetes and obesity. WO2008058961; 2008
   Google Scholar
• Novartis AG. New pyridine and pyrazine derivatives are CETP inhibitors – useful for the treatment of eg lipid metabolism disorders, cardiovascular disease, stroke, diabetes and obesity. WO2008058967; 2008
   Google Scholar
• Kowa Co. Ltd. New 2-(benzyl(pyridylmethyl)amino)pyrimidine compounds are cholesterol ester transfer protein inhibitors – for treating and preventing e.g. hyperlipidemia, arteriosclerois and peripheral vascular disease. WO2008018529; 2008
   Google Scholar
• Kowa Co. Ltd. New pyrimidine compounds are cholesterol ester transfer protein inhibitors – useful for treating and preventing hyperlipidemia, arterosclerosis, peripheral vascular disease, cardiovascular disorders, angina pectoris, ischemia, myocardial ischemia, thrombosis, reperfusion disorders, and hypertension. WO2008111604; 2008
   Google Scholar
• Kowa Co. Ltd. New pyrimidine compounds are cholesterol ester transfer protein inhibitors – useful for treating and preventing hyperlipidemia, arterosclerosis, peripheral vascular disease, cardiovascular disorders, angina pectoris, ischemia, myocardial ischemia, thrombosis, reperfusion disorders, and hypertension. WO2008129951; 2008
   Google Scholar
• Davidson MH, McKenney JM, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesterol ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 2006;48:1774-81
   PubMed Web of Science ®Google Scholar
• McKenney JM, Davidson MH, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesterol ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atrovastatin. J AM Coll Cardiol 2006;48:1782-90
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity. A pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008;118:2515-22
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L, et al. RADIANCE 2 investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW, et al. RADIANCE 2 investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Evans GW, et al. Design of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis. Curr Med Res Opin 2007;23:885-94
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis. Insight from ILLUSTRATE (investigation of lipid level management using coronary ultrasound to assess reduction of atherosclerosis by CETP inhibition and HDL elevation). Circulation 2008;118:2506-14
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
   PubMed Web of Science ®Google Scholar
• Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008;154:1465-73
   PubMed Web of Science ®Google Scholar
• Monsanto Co. Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity. WO00018721; 2000
   Google Scholar
• Monsanto Co. Substituted N-aliphatic-N-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity. WO00018723; 2000
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Novel aminoethanol derivatives useful for the treatment of hyperlipidemia. WO02059077; 2002
   Google Scholar
• Pfizer Products, Inc. New substituted 1,1,1-trifluoro-3-[(benzyl)(pyrimidin-2-yl)amino]propan-2-ol derivatives – useful for the treatment of cardiovascular and lipid metabolism disorders. WO2006090250; 2006
   Google Scholar
• Bristol-Myers Squibb Co. New tertiary amine and related derivatives are CETP inhibitors – useful for the treatment of eg atherosclerosis, obesity and lipid metabolism disorders. WO2007062342; 2007
   Google Scholar
• Bristol-Myers Squibb Co. New tertiary amine and related derivatives are CETP inhibitors – useful for the treatment of eg atherosclerosis, obesity and lipid metabolism disorders. WO2007062314; 2007
   Google Scholar
• Bristol-Myers Squibb Co. New 1,1-diphenyl-methylamine and related derivatives are CETP inhibitors – useful for the treatment of eg atherosclerosis, obesity and lipid metabolism disorders. WO2007062308; 2007
   Google Scholar
• F Hoffmann-La Roche Ltd. New indole, indazole and indoline derivatives are cholesteryl ester transfer protein inhibitors – useful for the treatment of cardiovascular and lipid metabolism disorders. WO2006013048; 2006
   Google Scholar
• F Hoffmann-La Roche Ltd. New anthranilamide and 2-aminoheteroarene carboxamide derivatives are cholesteryl ester transfer protein inhibitors – useful for the treatment of eg lipid metabolism disorders, atherosclerosis and cardiovascular disease. WO2007090752; 2007
   Google Scholar
• Merck & Co, Inc. New heterocyclic derivatives are CETP inhibitors – useful for the treatment of atherosclerosis. WO2007070173; 2007
   Google Scholar
• Merck & Co, Inc. Novel benzoxazole arylamide compounds are CETP inhibitors – useful for the treatment of atherosclerosis. WO2008156715; 2008
   Google Scholar
• Merck & Co, Inc. Novel benzoxazole arylamide compounds are CETP inhibitors – useful for the treatment of atherosclerosis. WO2008156718; 2008
   Google Scholar
• Merck & Co, Inc. Novel benzoxazole arylamide compounds are CETP inhibitors – useful for the treatment of atherosclerosis. WO2008156717; 2008
   Google Scholar
• Bayer HealthCare AG. New chromanol derivatives are CETP inhibitors – useful for the treatment of eg coronary heart disease, dyslipidemia, arteriosclerosis, restenosis, obesity, diabetes, metabolic syndrome, stroke and Alzheimer's disease. WO2007107243; 2007
   Google Scholar
• Joy TR, Hegele RA. Commentary. The failure of torcetrapib: what have we learned? Br J Pharmacol 2008;154:1379-81
   Google Scholar
• Farrell B, Godwin J, Richards S. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar